Former Allergan exec to take reins at Amneal

Robert Stewart will become president of Amneal Pharmaceuticals LLC in January.

He will then take the helm as CEO and president after Bridgewater-based Amneal and Impax Laboratories Inc. combine.

Stewart, 50, most recently served as chief operating officer of Allergan PLC.

Following the close of the deal, Impax CEO and President Paul Bisaro will become executive chairman. Amneal’s co-CEOs and co-founders, Chirag and Chintu Patel, will serve as co-chairmen of the combined company’s board of directors.

“We are excited that Rob will be joining Amneal,” Chirag Patel said. “He is a great leader to inspire our team as we prepare for the expected combination with Impax and next phase of our growth in becoming a leading, affordable health care company.”

Chintu Patel agreed: “Rob is a highly respected leader with a wealth of pharmaceutical expertise, which will further enhance our team of world-class leaders focused on creating value for patients, customers, employees and shareholders.”

Stewart will work closely with Amneal’s co-CEOs in leading its current business and will play a key role in guiding the pre-integration planning work for the announced combination with Impax, which is currently expected to occur in the first half of next year.

“Rob is the right executive to lead the combined company,” Bisaro said. “He brings an ideal mix of strong operating leadership, deep experience in both the brand and generics sectors, and a proven track record of driving success and capturing synergies through numerous complex integrations. I look forward to working closely with Rob again, and providing my full support to the integration effort as well as continuing to focus on creative long-term growth strategies.”

Stewart said he is ” honored and excited to work with the Amneal and Impax teams.”

“The combination creates a dynamic leader in generics and specialty pharmaceuticals, with a deep and rich pipeline of products and integrated global manufacturing platform for strong continued profitable growth,” he said.  “I look forward to leading the teams and helping the organization achieve its long-term goals.”

Stewart has 22 years of experience in global brand and generic pharmaceutical leadership, with expertise in all aspects of operations and integration.